An early pioneer is SetPoint Medical, a Californian company in which GSK’s new Action Potential Venture Capital Fund is investing $5m. It is developing a small electronic implant to stimulate the vagus nerve in the neck. This resets the immune system to make less of the inflammatory molecules that contribute to rheumatoid arthritis and Crohn’s disease.
